Search for other papers by Jan Calissendorff in
Google Scholar
PubMed
Centre for Clinical Research in Sörmland, Uppsala University, Uppsala, Sweden
Search for other papers by Emil Mikulski in
Google Scholar
PubMed
Search for other papers by Erik H. Larsen in
Google Scholar
PubMed
Centre for Clinical Research in Sörmland, Uppsala University, Uppsala, Sweden
Search for other papers by Marika Möller in
Google Scholar
PubMed
all investigators [ 13 ]. As auto-antibodies did not change in these patients with autoimmune hyperthyroidism, Se does not appear to affect immunoglobulins in GD. Increased SePP concentration, in its capacity as a Se transporter protein, could
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
Search for other papers by Camilla Bøgelund Larsen in
Google Scholar
PubMed
Search for other papers by Eva Rabing Brix Petersen in
Google Scholar
PubMed
Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark
Search for other papers by Martin Overgaard in
Google Scholar
PubMed
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
Search for other papers by Steen Joop Bonnema in
Google Scholar
PubMed
the increased TSH had prompted a trial of levothyroxine (LT4) replacement therapy on the suspicion of thyroid failure. Up to 150 µg LT4 per day was given. Hereby, plasma TSH decreased to near-normal levels within a few weeks, but hyperthyroid symptoms
Search for other papers by Gerd Krause in
Google Scholar
PubMed
Search for other papers by Anja Eckstein in
Google Scholar
PubMed
Search for other papers by Ralf Schülein in
Google Scholar
PubMed
]. Pathological activation of the TSHR by TSHR-stimulating autoimmune antibodies (TSAb) leads to the uncontrolled production of thyroid hormones T3 and T4 in the thyroid causing hyperthyroidism in Graves’ disease (GD) [ 5 ]. The TSAb binds to the TSHR at a similar
Search for other papers by Roberto Negro in
Google Scholar
PubMed
Search for other papers by Roberto Attanasio in
Google Scholar
PubMed
Search for other papers by Franco Grimaldi in
Google Scholar
PubMed
Search for other papers by Claudio Marcocci in
Google Scholar
PubMed
Search for other papers by Rinaldo Guglielmi in
Google Scholar
PubMed
Search for other papers by Enrico Papini in
Google Scholar
PubMed
/day in 21% of cases, 100-200 µg/day in 60.2%, and >200 µg/day in 18.8% (p < 0.01). About half of the respondents would recommend Se supplementation for a patient in remission from hyperthyroidism for 18 months and with a clinical activity score of 2
Search for other papers by Federica D’Aurizio in
Google Scholar
PubMed
Search for other papers by Alessia Biasotto in
Google Scholar
PubMed
Search for other papers by Claudia Cipri in
Google Scholar
PubMed
Search for other papers by Franco Grimaldi in
Google Scholar
PubMed
Search for other papers by Jessica Zucco in
Google Scholar
PubMed
Search for other papers by Stefania Marzinotto in
Google Scholar
PubMed
Department of Medicine, University of Udine, Udine, Italy
Search for other papers by Francesco Curcio in
Google Scholar
PubMed
Search for other papers by Salvatore Benvenga in
Google Scholar
PubMed
examination. Such symptoms, suggestive of hyperthyroidism/thyrotoxicosis, prompted a further evaluation of TFT. Although TSH continued to be normal, high levels of free thyroid hormones (FT4 = 39.7 pmol/L; FT3 = 15.2 pmol/L) were interpreted as evidence of
Search for other papers by Sofie Larsen Rasmussen in
Google Scholar
PubMed
Search for other papers by Lars Rejnmark in
Google Scholar
PubMed
Search for other papers by Eva Ebbehøj in
Google Scholar
PubMed
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Search for other papers by Åse Krogh Rasmussen in
Google Scholar
PubMed
Search for other papers by Jakob Bue Bjorner in
Google Scholar
PubMed
Search for other papers by Torquil Watt in
Google Scholar
PubMed
and the electronic version of the ThyPRO questionnaire [ 1 ]. Methods Study Population We included patients with a diagnosis of Graves' hyperthyroidism or autoimmune hypothyroidism who were in a clinically stable phase of their disease and
Search for other papers by Joanna Bogusławska in
Google Scholar
PubMed
Search for other papers by Marlena Godlewska in
Google Scholar
PubMed
Search for other papers by Ewa Gajda in
Google Scholar
PubMed
Search for other papers by Agnieszka Piekiełko-Witkowska in
Google Scholar
PubMed
hypothyroidism. In contrast, GD is mainly associated with hyperthyroidism, resulting from the presence of thyroid-stimulating antibodies which activate thyrotropin receptor (TSHR) on thyrocytes, leading to thyroid hyperplasia. Only a minor number of GD patients
Search for other papers by Johannes W. Dietrich in
Google Scholar
PubMed
Heart Center Bad Neustadt, Clinic for Interventional Electrophysiology, Bad Neustadt an der Saale, Germany
Search for other papers by Patrick Müller in
Google Scholar
PubMed
Search for other papers by Fabian Schiedat in
Google Scholar
PubMed
Search for other papers by Markus Schlömicher in
Google Scholar
PubMed
Search for other papers by Justus Strauch in
Google Scholar
PubMed
Search for other papers by Apostolos Chatzitomaris in
Google Scholar
PubMed
Search for other papers by Harald H. Klein in
Google Scholar
PubMed
Search for other papers by Andreas Mügge in
Google Scholar
PubMed
Search for other papers by Josef Köhrle in
Google Scholar
PubMed
Search for other papers by Eddy Rijntjes in
Google Scholar
PubMed
Search for other papers by Ina Lehmphul in
Google Scholar
PubMed
and atrial fibrillation (AF) are classical consequences of thyrotoxicosis included in two scoring systems for estimating the probability of thyroid storm [ 16 ]. Even subclinical hyperthyroidism is associated with increased risk for AF [ 17 ] and a
Search for other papers by Susanne Neumann in
Google Scholar
PubMed
Search for other papers by Christine C. Krieger in
Google Scholar
PubMed
Search for other papers by Marvin C. Gershengorn in
Google Scholar
PubMed
Graves’ hyperthyroidism (GH) [ 9 ] and does not bind to IGF-1R [ 10 ], was inhibited by the IGF-1R antagonist linsitinib [ 6 ]; (3) stimulation by M22 and immunoglobulins purified from the sera of Graves’ disease (GD) patients with eye disease (GO
Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam, The Netherlands
Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands
Search for other papers by Heleen I Jansen in
Google Scholar
PubMed
Search for other papers by Antonius E van Herwaarden in
Google Scholar
PubMed
Search for other papers by Henk J Huijgen in
Google Scholar
PubMed
Amsterdam Reproduction & Development Research Institute, Amsterdam, The Netherlands
Search for other papers by Rebecca C Painter in
Google Scholar
PubMed
Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands
Search for other papers by Jacquelien J Hillebrand in
Google Scholar
PubMed
Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands
Amsterdam Reproduction & Development Research Institute, Amsterdam, The Netherlands
Search for other papers by Anita Boelen in
Google Scholar
PubMed
Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam, The Netherlands
Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands
Amsterdam Reproduction & Development Research Institute, Amsterdam, The Netherlands
Search for other papers by Annemieke C Heijboer in
Google Scholar
PubMed
pregnancy, since the fetus does not produce thyroid hormone itself until 16–20 weeks ( 7 ). Untreated maternal hyperthyroidism can not only have fetal consequences such as intra-uterine growth restriction but also life-threatening maternal consequences as